ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy
ScaleReady has awarded a $200,000 G-Rex® Grant to March Biosciences to advance the manufacturing of MB-105, a novel CAR-T cell therapy. The therapy targets CD5 for patients with T-cell lymphomas and received FDA orphan drug designation in January 2025.
MB-105 is being developed for multiple CD5-positive blood cancers, including T-cell lymphoma, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma. The therapy's proprietary design allows it to target malignant cells while preserving normal T-cell function.
The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, provides up to $300,000 per recipient. Grant recipients gain access to ScaleReady's consortium of partners, offering expertise in:
- cGMP manufacturing
- Quality and regulatory affairs
- CGT business operations
The program has been extended with millions in additional funding to continue supporting cell and gene therapy development.
ScaleReady ha assegnato una G-Rex® Grant da 200.000 dollari a March Biosciences per avanzare nella produzione di MB-105, una nuova terapia CAR-T. Questa terapia è mirata al CD5 per pazienti con linfomi a cellule T e ha ottenuto la designazione di farmaco orfano dalla FDA nel gennaio 2025.
MB-105 è in fase di sviluppo per diversi tumori del sangue CD5-positivi, tra cui linfoma a cellule T, leucemia linfoblastica acuta a cellule T, leucemia linfatica cronica e linfoma a cellule del mantello. Il design proprietario della terapia consente di colpire le cellule maligne preservando la normale funzione delle cellule T.
Il Programma G-Rex Grant, che ha assegnato quasi 200 sovvenzioni con oltre 50 nuove domande in attesa, offre fino a 300.000 dollari per beneficiario. I destinatari della sovvenzione accedono al consorzio di partner di ScaleReady, che offre competenze in:
- produzione cGMP
- affari regolatori e di qualità
- operazioni commerciali CGT
Il programma è stato esteso con milioni di finanziamenti aggiuntivi per continuare a supportare lo sviluppo di terapie cellulari e geniche.
ScaleReady ha otorgado una Subvención G-Rex® de 200,000 dólares a March Biosciences para avanzar en la fabricación de MB-105, una novedosa terapia CAR-T. Esta terapia está dirigida al CD5 para pacientes con linfomas de células T y recibió la designación de medicamento huérfano por la FDA en enero de 2025.
MB-105 se está desarrollando para varios cánceres de sangre CD5-positivos, incluyendo linfoma de células T, leucemia linfoblástica aguda de células T, leucemia linfocítica crónica y linfoma de células del manto. El diseño propietario de la terapia permite atacar las células malignas preservando la función normal de las células T.
El Programa de Subvenciones G-Rex, que ha otorgado casi 200 subvenciones y tiene más de 50 nuevas solicitudes pendientes, ofrece hasta 300,000 dólares por beneficiario. Los beneficiarios acceden al consorcio de socios de ScaleReady, que ofrece experiencia en:
- fabricación cGMP
- calidad y asuntos regulatorios
- operaciones comerciales CGT
El programa ha sido ampliado con millones en fondos adicionales para continuar apoyando el desarrollo de terapias celulares y génicas.
ScaleReady가 March Biosciences에 MB-105의 제조를 촉진하기 위해 20만 달러 규모의 G-Rex® 보조금을 수여했습니다. MB-105는 T세포 림프종 환자를 대상으로 하는 새로운 CAR-T 세포 치료제로, 2025년 1월 FDA 희귀의약품 지정을 받았습니다.
MB-105는 T세포 림프종, T세포 급성 림프모구성 백혈병, 만성 림프구성 백혈병, 만틀 세포 림프종 등 여러 CD5 양성 혈액암 치료를 위해 개발 중입니다. 이 치료법의 독점 설계는 정상 T세포 기능은 유지하면서 악성 세포만을 표적할 수 있도록 합니다.
거의 200건의 보조금을 수여하고 50건 이상의 신규 신청이 대기 중인 G-Rex 보조금 프로그램은 수혜자당 최대 30만 달러를 지원합니다. 보조금 수혜자는 ScaleReady의 파트너 컨소시엄에 접근할 수 있으며, 다음 분야의 전문 지식을 제공합니다:
- cGMP 제조
- 품질 및 규제 업무
- CGT 사업 운영
이 프로그램은 세포 및 유전자 치료 개발 지원을 계속하기 위해 수백만 달러의 추가 자금으로 연장되었습니다.
ScaleReady a attribué une subvention G-Rex® de 200 000 $ à March Biosciences pour faire progresser la fabrication de MB-105, une nouvelle thérapie par cellules CAR-T. Cette thérapie cible le CD5 chez les patients atteints de lymphomes à cellules T et a reçu la désignation de médicament orphelin par la FDA en janvier 2025.
MB-105 est en cours de développement pour plusieurs cancers du sang CD5-positifs, notamment le lymphome à cellules T, la leucémie aiguë lymphoblastique à cellules T, la leucémie lymphoïde chronique et le lymphome à cellules du manteau. La conception propriétaire de la thérapie lui permet de cibler les cellules malignes tout en préservant la fonction normale des cellules T.
Le programme de subventions G-Rex, qui a attribué près de 200 subventions et compte plus de 50 nouvelles demandes en attente, offre jusqu'à 300 000 $ par bénéficiaire. Les bénéficiaires ont accès au consortium de partenaires de ScaleReady, offrant une expertise en :
- fabrication cGMP
- affaires réglementaires et qualité
- opérations commerciales CGT
Le programme a été prolongé avec plusieurs millions de financements supplémentaires pour continuer à soutenir le développement des thérapies cellulaires et géniques.
ScaleReady hat March Biosciences einen G-Rex® Zuschuss in Höhe von 200.000 USD zur Förderung der Herstellung von MB-105, einer neuartigen CAR-T-Zelltherapie, gewährt. Die Therapie richtet sich gegen CD5 bei Patienten mit T-Zell-Lymphomen und erhielt im Januar 2025 die Orphan-Drug-Designation der FDA.
MB-105 wird für verschiedene CD5-positive Blutkrebserkrankungen entwickelt, darunter T-Zell-Lymphom, T-zellige akute lymphoblastische Leukämie, chronische lymphatische Leukämie und Mantelzell-Lymphom. Das proprietäre Design der Therapie ermöglicht es, bösartige Zellen gezielt zu bekämpfen und gleichzeitig die normale T-Zell-Funktion zu erhalten.
Das G-Rex Grant Programm, das bisher fast 200 Zuschüsse vergeben hat und über 50 neue Anträge in Bearbeitung hat, bietet jedem Empfänger bis zu 300.000 USD. Die Stipendiaten erhalten Zugang zum Partnerkonsortium von ScaleReady, das Fachwissen in folgenden Bereichen bietet:
- cGMP-Herstellung
- Qualitäts- und Regulierungsangelegenheiten
- CGT-Geschäftsbetrieb
Das Programm wurde mit zusätzlichen Millionen an Fördermitteln verlängert, um die Entwicklung von Zell- und Gentherapien weiterhin zu unterstützen.
- Secured $200,000 G-Rex Grant funding for advancing CAR-T cell therapy manufacturing
- FDA orphan drug designation received for MB-105 in January 2025
- Multiple potential revenue streams with MB-105 targeting various indications (TCL, T-ALL, CLL, MCL, B-NHL)
- Proprietary CAR design technology that differentiates from competitors
- Part of growing consortium with access to cGMP manufacturing and regulatory expertise
- Still in clinical development phase - no immediate revenue generation
- Manufacturing costs for autologous CAR-T remain high despite optimization efforts
- Dependent on grant funding for development, indicating possible capital constraints
Insights
ScaleReady's G-Rex Grant Program demonstrates Bio-Techne's strategic positioning in cell therapy manufacturing, though immediate financial impact appears limited.
The $200,000 G-Rex Grant awarded to March Biosciences highlights Bio-Techne's ongoing strategy to establish its manufacturing technology in the expanding cell and gene therapy market. As part of the ScaleReady collaboration (which includes Bio-Techne, Wilson Wolf Manufacturing, and CellReady), this grant program serves as both a marketing vehicle and technology validation mechanism for the G-Rex bioreactor platform.
What makes this program strategically valuable is its scale and potential for relationship building. With nearly 200 grants awarded and millions in additional funding, Bio-Techne is creating a significant footprint in the cell therapy manufacturing ecosystem. Each grant recipient becomes a potential long-term customer as their therapies advance toward commercialization.
The G-Rex technology addresses critical manufacturing challenges for cell therapies like MB-105, which recently received FDA orphan drug designation. Dr. Mamonkin's statement that the G-Rex bioreactor will "reduce complexity, time, and costs" in manufacturing highlights the value proposition of Bio-Techne's technology in this growing market.
While a single grant doesn't materially impact Bio-Techne's finances, the cumulative effect of hundreds of grants could create a significant installed base of G-Rex users. This "land and expand" approach is common in biotechnology, where initial technology adoption can lead to expanded usage as therapies progress through clinical development and commercialization.
The cell and gene therapy market continues to grow rapidly, with manufacturing solutions representing a critical bottleneck. By positioning its technology as an enabling platform for innovative therapies, Bio-Techne is executing on its strategy to capture value in this expanding market segment.
"As we ramp up clinical manufacturing and advance towards commercialization of MB-105, scalability continues to be an important focal point. This grant will enable continued development of a robust cGMP process with the G-Rex bioreactor to further reduce complexity, time, and costs incurred with manufacturing autologous CAR-T products," says Dr. Maksim Mamonkin, Chief Scientific Officer at March Biosciences.
"We understand how to overcome the scalability and efficiency barriers that March Biosciences faced with manufacturing an autologous CAR-T product and are happy to help March Biosciences establish nimble MB-105 manufacturing with a G-Rex Grant" said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex.
As part of the G-Rex Grant, March Biosciences will continue development of a G-Rex-centric fully integrated CAR-T cell manufacturing process to further streamline the scalable cGMP production of MB-105 and other CAR-T products in the research pipeline.
In January 2025, March Biosciences received
ScaleReady's G-Rex Grant Program is advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to
For more information about the G-Rex® Grant Program, please contact info@scaleready.com.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
About MB-105
MB-105 is an orphan-drug designated, first-in-class autologous CD5-targeted CAR-T cell therapy in development for CD5-positive hematologic malignancies, including T-cell lymphoma (TCL), T-cell acute lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL), and other CD5+ B cell non-Hodgkin's Lymphoma (B-NHL) indications. The therapy employs a proprietary CAR design that enables selective targeting of malignant cells while preserving normal T-cell function. The Phase 2 clinical trial of MB-105 (NCT06534060) is currently enrolling for patients with relapsed / refractory T cell lymphoma.
About March Biosciences
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Any statement describing March Biosciences' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "should," "would," "seeks," "aims," "plans," "potential," "will," "milestone" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in these forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the clinical development of MB-105, the progress of clinical trials for pipeline candidates, regulatory approvals, market demand for new therapies, competitive dynamics in the biotechnology sector, and macroeconomic conditions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-march-biosciences-as-recipient-of-g-rex-grant-to-advance-manufacturing-of-novel-car-t-cell-therapy-302435883.html
SOURCE Bio-Techne Corporation
FAQ
What is the value of ScaleReady's G-Rex Grant awarded to March Biosciences in 2025?
How will March Biosciences use the G-Rex Grant for MB-105 manufacturing?
What FDA designations has March Biosciences received for MB-105 therapy?
Which types of cancer does March Biosciences' MB-105 therapy target?
How many G-Rex Grants has ScaleReady awarded to date?
